pd 153035 has been researched along with gefitinib in 23 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 8 (34.78) | 29.6817 |
2010's | 15 (65.22) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cheung, K; Dushin, RG; Floyd, MB; Fraser, HL; Ingalls, CL; Loganzo, F; Nittoli, T; Ravi, MR; Tan, X; Wissner, A | 1 |
Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M | 1 |
Chen, Z; Lou, Y; Yu, Y; Zhang, Y | 1 |
Depreux, P; Farce, A; Garofalo, A; Goossens, L; Lemoine, A; Ravez, S; Six, P | 1 |
Gallus, J; Juvale, K; Wiese, M | 1 |
Abou El Ella, DA; Aly, RM; El-Motwally, AM; Ibrahim, DA | 1 |
Hu, L; Li, Z; Liu, P; Pan, Z; Qin, X; Yang, L; Zeng, C | 1 |
Guo, Y; He, J; Li, Y; Liu, M; Liu, Y; Xiao, J; Yu, W; Zhang, Q | 1 |
Das, D; Hong, J | 1 |
Asquith, CRM; Drewry, DH; East, MP; Havener, TM; Johnson, GL; Laitinen, T; Morris, DC; Naegeli, KM; Wells, CI; Zuercher, WJ | 1 |
Asquith, CRM; Treiber, DK; Zuercher, WJ | 1 |
Asquith, CRM; Crona, DJ; Fleck, N; Grundner, C; Torrice, CD; Zuercher, WJ | 1 |
Klar, U; Lichtner, RB; Menrad, A; Schneider, MR; Sommer, A | 1 |
Chang, CM; Li, B; McKenna, WG; Shu, HK; Yuan, M | 1 |
Chansel, D; Chatziantoniou, C; Dussaule, JC; Flamant, M; François, H; Placier, S; Tharaux, PL | 1 |
Gaiger, A; Grunt, TW; Kainz, B; Köhler, G; Puckmair, K; Rünzler, D; Tomek, K; Wagner, R; Zielinski, CC | 1 |
Breza, N; Keri, G; Orfi, L; Petak, I; Pinter, F; Robert, K; Schwab, R; Varkondi, E | 1 |
Muro, Y; Shimoyama, Y; Sugiura, K; Tomita, Y; Yamaki, M | 1 |
Haramoto, M; Horibe, T; Kawakami, K; Kohno, M; Matsuzaki, K; Nakajima, O; Ohara, K; Yano, Y | 1 |
Pick, A; Wiese, M | 1 |
Matsuo, K; Takada, Y | 1 |
Eda, T; Iwakura, Y; Mizuno, M; Nagata, K; Namba, H; Nawa, H; Okubo, T; Shibuya, M; Sotoyama, H; Wang, R | 1 |
Liu, W; Qin, ZP; Xing, RC; Yao, RC; Zheng, J; Zheng, WH | 1 |
2 review(s) available for pd 153035 and gefitinib
Article | Year |
---|---|
The association between anti-tumor potency and structure-activity of protein-kinases inhibitors based on quinazoline molecular skeleton.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Humans; Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Quinazolines | 2019 |
Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry.
Topics: Animals; Antineoplastic Agents; Chemistry Techniques, Synthetic; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2019 |
21 other study(ies) available for pd 153035 and gefitinib
Article | Year |
---|---|
Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2.
Topics: Adenosine Triphosphate; Binding Sites; Biological Assay; Cells, Cultured; ErbB Receptors; Humans; Inhibitory Concentration 50; Models, Molecular; Molecular Structure; Protein Conformation; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor Receptor-2 | 2007 |
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases | 2007 |
2,3-Disubstituted 8-arylamino-3H-imidazo[4,5-g]quinazolines: a novel class of antitumor agents.
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; Female; Humans; Male; Quinazolines | 2009 |
Impact of aryloxy-linked quinazolines: a novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors.
Topics: Cell Line, Tumor; Cell Proliferation; Humans; Models, Molecular; Quinazolines; Receptor Protein-Tyrosine Kinases; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
Investigation of quinazolines as inhibitors of breast cancer resistance protein (ABCG2).
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cells, Cultured; Dogs; Dose-Response Relationship, Drug; Humans; Molecular Structure; Neoplasm Proteins; Quinazolines; Structure-Activity Relationship | 2013 |
Molecular design and synthesis of certain new quinoline derivatives having potential anticancer activity.
Topics: Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; MCF-7 Cells; Molecular Structure; Protein Kinase Inhibitors; Quinolines; Structure-Activity Relationship | 2015 |
Discovery of new [1,4]dioxino[2,3-f]quinazoline-based inhibitors of EGFR including the T790M/L858R mutant.
Topics: A549 Cells; Antineoplastic Agents; Cell Proliferation; Drug Discovery; ErbB Receptors; Humans; Inhibitory Concentration 50; Lung Neoplasms; Molecular Structure; Mutation; Protein Binding; Quinazolines | 2016 |
Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
Topics: Aminoquinolines; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chordoma; Drug Design; ErbB Receptors; HEK293 Cells; Humans; Intracellular Signaling Peptides and Proteins; Molecular Docking Simulation; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines | 2019 |
Utilizing comprehensive and mini-kinome panels to optimize the selectivity of quinoline inhibitors for cyclin G associated kinase (GAK).
Topics: Cyclin G; Humans; Protein Kinase Inhibitors; Quinolines | 2019 |
Anti-tubercular activity of novel 4-anilinoquinolines and 4-anilinoquinazolines.
Topics: Aniline Compounds; Antitubercular Agents; Dose-Response Relationship, Drug; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Quinazolines; Quinolines; Structure-Activity Relationship | 2019 |
Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Squamous Cell; Cell Division; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Kinetics; Ligands; Lung Neoplasms; Mammary Neoplasms, Experimental; Phthalimides; Quinazolines; Rats; Signal Transduction; Tumor Cells, Cultured | 2001 |
Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
Topics: Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; DNA-Binding Proteins; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Glioma; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; STAT3 Transcription Factor; Trans-Activators; Tumor Suppressor Proteins | 2003 |
Prevention of renal vascular and glomerular fibrosis by epidermal growth factor receptor inhibition.
Topics: Animals; Capillaries; Collagen; Collagen Type I; Creatinine; Endothelin-1; ErbB Receptors; Fibrosis; Gefitinib; Gene Expression Regulation; Genes, Reporter; Glomerulosclerosis, Focal Segmental; Hypertension; Ischemia; Kidney; Kidney Cortex; Kidney Diseases; Kidney Glomerulus; Male; MAP Kinase Signaling System; Mice; Mice, Transgenic; Necrosis; NG-Nitroarginine Methyl Ester; Nitric Oxide; Phosphorylation; Promoter Regions, Genetic; Protein Processing, Post-Translational; Proteinuria; Quinazolines; Rats; Rats, Sprague-Dawley | 2004 |
Upregulation of retinoic acid receptor-beta by the epidermal growth factor-receptor inhibitor PD153035 is not mediated by blockade of ErbB pathways.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Division; Cell Line, Tumor; CpG Islands; DNA Methylation; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Ovarian Neoplasms; Quinazolines; Receptors, Retinoic Acid; RNA Processing, Post-Transcriptional; Transcription, Genetic; Tyrphostins; Up-Regulation | 2007 |
Biochemical assay-based selectivity profiling of clinically relevant kinase inhibitors on mutant forms of EGF receptor.
Topics: Aminoquinolines; Aniline Compounds; Biological Assay; Drug Resistance; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Inhibitory Concentration 50; Morpholines; Mutant Proteins; Protein Kinase Inhibitors; Quinazolines; Substrate Specificity; Tyrphostins | 2008 |
Epidermal growth factor receptor tyrosine kinase inhibitors induce CCL2 and CCL5 via reduction in IL-1R2 in keratinocytes.
Topics: Acneiform Eruptions; Adolescent; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cell Line; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; Interleukin-1; Keratinocytes; Lung Neoplasms; Male; Middle Aged; Quinazolines; Receptors, Interleukin-1; Receptors, Interleukin-1 Type II; RNA, Messenger; Signal Transduction | 2010 |
A novel hybrid peptide targeting EGFR-expressing cancers.
Topics: Animals; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mice; Mutant Chimeric Proteins; Neoplasm Transplantation; Neoplasms; Quinazolines; Receptor Protein-Tyrosine Kinases; Transplantation, Heterologous | 2011 |
Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Benzimidazoles; Cell Line; Cetuximab; Chromones; Dose-Response Relationship, Drug; Drug Resistance, Multiple; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Morpholines; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines; Signal Transduction; Tyrphostins | 2012 |
Gefitinib, but not erlotinib, is a possible inducer of Fra-1-mediated interstitial lung disease.
Topics: Animals; Antineoplastic Agents; Chemokine CCL2; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation; Lipopolysaccharides; Lung Diseases, Interstitial; Macrophages; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Primary Cell Culture; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-fos; Quinazolines; RNA, Messenger; Tumor Necrosis Factor-alpha | 2012 |
ErbB inhibitors ameliorate behavioral impairments of an animal model for schizophrenia: implication of their dopamine-modulatory actions.
Topics: Animals; Antipsychotic Agents; Brain Chemistry; Disease Models, Animal; Dopaminergic Neurons; Dose-Response Relationship, Drug; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Male; Motor Activity; Quinazolines; Rats; Rats, Sprague-Dawley; Reflex, Startle; Schizophrenia; Schizophrenic Psychology | 2013 |
Relevance of E-cadherin expression to EGFR-TKI molecular targeted therapy sensitivity/resistance and its clinical significance.
Topics: Breast Neoplasms; Cadherins; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2015 |